LENZ Therapeutics (LENZ) Non Operating Income (2020 - 2026)
LENZ Therapeutics (LENZ) reported Non Operating Income of $2.6 million for Q1 2026, up 14.49% year-over-year from $2.3 million in Q1 2025, and up 136.83% on a QoQ basis from -$7.2 million in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Non Operating Income data on file, last reported at $2.6 million in Q1 2026.
- Quarterly Non Operating Income rose 14.49% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 million (down 132.22% YoY) and the FY2025 annual result came in at -$243000.0, down 184.08% from the prior year.
- Non Operating Income advanced to $2.6 million in Q1 2026 per LENZ's latest filing, from -$7.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.7 million in Q3 2024 and bottomed at -$7.2 million in Q4 2025.
- The 5-year median for Non Operating Income is $250000.0 (2023), against an average of $415187.5.
- The widest annual swing landed in 2022, when Non Operating Income soared 20900.0%; it then slumped 89937.5% in 2025.
- Tracing LENZ's Non Operating Income over 5 years: stood at $2.2 million in 2022, then sank by 87.59% to $267000.0 in 2023, then tumbled by 97.0% to $8000.0 in 2024, then tumbled by 89937.5% to -$7.2 million in 2025, then soared by 136.83% to $2.6 million in 2026.
- Per Business Quant, the three latest LENZ Non Operating Income figures stand at $2.6 million (Q1 2026), -$7.2 million (Q4 2025), and $2.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | 2.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.65 Mn |
| Dec 31, 2025 | -7.19 Mn |
| Sep 30, 2025 | 2.19 Mn |
| Jun 30, 2025 | 199,000.00 |
| Mar 31, 2025 | 2.31 Mn |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 1.64 Mn |
| Mar 31, 2024 | -1.35 Mn |
| Dec 31, 2023 | 267,000.00 |
| Sep 30, 2023 | -101,000.00 |
| Jun 30, 2023 | 233,000.00 |
| Mar 31, 2023 | -54,000.00 |
| Dec 31, 2022 | 2.15 Mn |
| Jun 30, 2022 | 840,000.00 |
| Mar 31, 2022 | 123,000.00 |
| Dec 31, 2021 | -10.33 Mn |
| Sep 30, 2021 | 10,000.00 |
| Jun 30, 2021 | 4,000.00 |
| Mar 31, 2021 | -10.34 Mn |
| Dec 31, 2020 | -55.21 Mn |
| Sep 30, 2020 | 380,000.00 |
| Jun 30, 2020 | -20,000.00 |